FABP5

Artelo Biosciences Reports Positive Pre-Clinical Results with its Novel Inhibitor to Fatty Acid Binding Protein 5

Retrieved on: 
Tuesday, August 16, 2022
Cortex, U.S. Securities and Exchange Commission, Securities Act of 1933, University, Cerebral cortex, Inflammation, Industry, Stony Brook University, GLOBE, Peripheral neuropathy, Cancer, Brain, Fear, Securities Exchange Act of 1934, Purging disorder, Security (finance), Research, Pain, Post-traumatic stress disorder, FABP5, Doctor of Philosophy, Lipid, Twitter, Cannabinoid, CB2, Anxiety, Nature, Neuroscience, Lead, FABP, Protein, Private Securities Litigation Reform Act, Screen for child anxiety related disorders, Diathesis–stress model, Nasdaq, PTSD, Organic acid, Pharmaceutical industry

President and Chief Executive Officer of Artelo Biosciences.

Key Points: 
  • President and Chief Executive Officer of Artelo Biosciences.
  • This new data further supports the development of our FABP inhibitor platform in anxiety-related disorders such as post-traumatic stress disorder.
  • We are encouraged by these findings which indicate inhibiting FABPs represents a promising neurobiological approach for the development of novel anxiety-inhibiting pharmacotherapies.
  • Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions.

Artelo Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, August 9, 2022
U.S. Securities and Exchange Commission, GLOBE, Cancer, Investment, Toxicity, Board, Purging disorder, AstraZeneca, Security (finance), Pain, Peripheral neuropathy, Patient, Appetite, Securities Act of 1933, Securities Exchange Act of 1934, Immune system, Inflammation, Industry, FABP5, Lipid, Cannabinoid, Șaeș, CB2, Nature, Board of directors, CB1, Nasdaq, Weight loss, Pharmacokinetics, Anorexia nervosa, Human, Compliance, 8-K, Radiation, Dehydration, Reverse stock split, Anxiety, FABP, Organic acid, RATS, Review, Oxaliplatin, Company, Twitter, Weight gain, Therapy, Protein, Private Securities Litigation Reform Act, Online gambling, Pharmaceutical industry

SOLANA BEACH, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, today reported financial and operating results for the three months ended June 30, 2022.

Key Points: 
  • The Companys common shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market commencing at the market open, August 10, 2022.
  • For further details, all shareholders are invited to review the 8-K regarding this reverse split filed today, August 9, 2022.
  • Financial Results Ended June 30, 2022
    Operating expenses for the three months ended June 30, 2022, were $2.4 million compared to $2.3 million for the same period in 2021.
  • Artelo Biosciences, Inc.is a clinical stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways including the endocannabinoid system.

Artelo Biosciences Presents Positive Pre-Clinical Results of ART26.12, a Novel FABP5 Inhibitor, in Alleviating Chemotherapy-Induced Pain

Retrieved on: 
Monday, June 27, 2022
FDA, Patient, Anxiety, Cannabinoid, Protein, National University of Ireland, Securities Act of 1933, Research, Securities Exchange Act of 1934, ICRS, Peripheral neuropathy, GLOBE, International Cannabinoid Research Society, Â, Cancer, Company, Industry, U.S. Securities and Exchange Commission, Lipid, Pain, FABP, Organic acid, Inflammation, Oxaliplatin, Therapy, Purging disorder, Drug Quality and Security Act, Cannabis, Clinical and Translational Science, Nasdaq, Private Securities Litigation Reform Act, Analgesic, Twitter, FABP5, Nature, Interest, National university, Security (finance), Pharmaceutical industry, CIPN

These results support further development of ART26.12 in neuropathy associated with chemotherapy and other neuropathies, continued Professor OSullivan.

Key Points: 
  • These results support further development of ART26.12 in neuropathy associated with chemotherapy and other neuropathies, continued Professor OSullivan.
  • Development of therapeutics for CIPN represents an attractive, new opportunity for Artelos FABP5 inhibitors, said Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences.
  • Various inhibitors of FABPs may be particularly useful for the treatment of specific cancers, neuropathic and nociceptive pain, and anxiety disorders.
  • Artelo Biosciences, Inc.is a clinical stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways including the endocannabinoid system.

Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following FDA Acceptance of Investigational New Drug Application for Phase 1 Clinical Trial in Non-Hodgkin’s Lymphoma

Retrieved on: 
Thursday, October 14, 2021
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, BCR, NSE, Program, Cancer, Hematological Cancer Research Investment and Education Act, FABP5, MALT1, Compliance, FDA, VISTA, Forward-looking statement, Twitter, Research, Acquisition, Large-cell lung carcinoma, CDK7, NYSE, Clinical trial, Patient, S&P, Food, Intellectual property, Midcap, DLBCL, Genetics, Drug discovery, EXEL, IND, Security (finance), American Association, SEC, Standard, Multimedia, Daiichi Sankyo, CBM, Mantle cell lymphoma, Esaxerenone, COVID-19, U.S. Securities and Exchange Commission, Nasdaq, Inflammation, BSE, Enzyme, NHL, RDY, Psoriasis, Safety, Pharmaceutical industry, Aurigene, Exelixis, AURIGENE, EXELIXIS

Exelixis has now assumed responsibility for the future clinical development, commercialization and global manufacturing of XL114.

Key Points: 
  • Exelixis has now assumed responsibility for the future clinical development, commercialization and global manufacturing of XL114.
  • Following the U.S. Food and Drug Administrations (FDA) recent acceptance of its Investigational New Drug (IND) application, Exelixis will soon initiate a phase 1 clinical trial evaluating XL114 monotherapy in patients with Non-Hodgkins lymphoma (NHL).
  • View the full release here: https://www.businesswire.com/news/home/20211014005549/en/
    XL114 is the second molecule that Exelixis in-licensed from Aurigene under the companies July 2019 collaboration, option and license agreement.
  • Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered trademarks of Exelixis, Inc. MINNEBRO is a registered trademark of Daiichi Sankyo Company, Limited.

Artelo Biosciences Expands Stony Brook Commercial License Agreement for FABP5 Platform for Development of Lead Cancer, Pain and Inflammation Compounds

Retrieved on: 
Monday, June 29, 2020
FABP5, Fatty acid-binding protein, Medication

Artelo has obtained exclusive rights to recently developed, third-generation fatty acid binding protein 5 (FABP5) inhibitors.

Key Points: 
  • Artelo has obtained exclusive rights to recently developed, third-generation fatty acid binding protein 5 (FABP5) inhibitors.
  • Many of the third generation FABP5 inhibitors have shown greater potency and/or selectivity to FABP5.
  • Stony Brooks recently awarded NCI grant further validates the FABP5 approach while providing non-dilutive funding to advance the development of product candidates arising from the platform.
  • Artelo Biosciences, Inc. is a San Diego-based biopharmaceutical company dedicated to the development and commercialization of proprietary therapeutics targeting the endocannabinoid system.

Artelo Biosciences Announces Publication of Positive Non-Clinical Fatty Acid Binding Protein 5 Inhibitor Data in Peer-Reviewed Journal

Retrieved on: 
Monday, November 18, 2019
Organic compounds, Cancer, RTT, Clinical medicine, Carbamates, Taxanes, Taxane, Cabazitaxel, Docetaxel, Prostate cancer, Chemotherapy, FABP5

(Docetaxel/cabazitaxel and fatty acid binding protein 5 inhibitors produce synergistic inhibition of prostate cancer growth, Carbonetti et.

Key Points: 
  • (Docetaxel/cabazitaxel and fatty acid binding protein 5 inhibitors produce synergistic inhibition of prostate cancer growth, Carbonetti et.
  • Taxanes, such as docetaxel and cabazitaxel are utilized in standard treatment regimens for chemotherapy nave castrationresistant prostate cancers.
  • FABP5 is an intra-cellular protein chaperone that serves as a carrier for fatty acids that trigger increased expression of genes associated with tumor angiogenesis and reduced patient survival.
  • Artelo Biosciences, Inc. is a San Diego-based biopharmaceutical company dedicated to the development and commercialization of proprietary therapeutics targeting the endocannabinoid system.

Artelo Biosciences Announces Five Year Commitment To Sponsor The Young Investigator Award At The International Cannabinoid Research Society Annual Symposium

Retrieved on: 
Tuesday, July 3, 2018
Cannabinoids, Neurochemistry, Fatty acid-binding protein, FABP5, Endocannabinoid system, Biochemistry

"The Young Investigator Award is a unique opportunity to identify and showcase researchers who have demonstrated dedication to endocannabinoid system research.

Key Points: 
  • "The Young Investigator Award is a unique opportunity to identify and showcase researchers who have demonstrated dedication to endocannabinoid system research.
  • We are extremely pleased to be an integral part of the conference as the sole sponsor of the award for the next five years," said Greg Gorgas, CEO of Artelo Biosciences.
  • Dr. Kaczocha is a leading research collaborator with ART26.12, a highly selective and highly potent fatty acid binding protein 5 (FABP5) inhibitor exclusively licensed to Artelo.
  • Artelo Biosciences, Inc. (OTCQB: ARTL) is aSan Diego-based biopharmaceutical company dedicated to the development and commercialization of proprietary therapeutics targeting the endocannabinoid system.